Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19

Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19

Multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.

In the patient group treated with hydroxychloroquine + azithromycin we expect to find a diminution of 20% or more regarding the evolution of acute respiratory syndrome, as opposed to patients who have not been treated with these medicines.

To date, there is no shown effective treatment regime for acute respiratory distress caused by COVID-19.

Inclusion Criteria:

• Patients with positive semi-quantitative PCR and COVID19 symptoms (fever, cough, diarrhea, dyspnoea, loss of smell).
• Signed informed consent

Exclusion Criteria:

• Retinal degeneration.
• Congenital or acquired long QT syndrome.
• Advanced liver failure.
• Renal insufficiency (incompatible with creatinine clearance less than 50 mL /minute).
• Allergic to hydroxychloroquine or azithromycin.
• Serious interaction with the drugs used.
• Pregnant or breastfeeding.
• Men and women in fertile and sexually active periods, who do not accept a highly effective contraceptive method.
• Inability to follow study procedures.